Health committee  Four minutes for me.

Health committee  It is still very much in development. The rate of change of technology will continue to drive costs down. It's not at all clear to me, based on what I know of the cancer treatment system, that costs for detailed genome analysis, even in a clinical setting, are prohibitive. If you consider that the direct costs of a bone marrow transplant are somewhat north of a quarter of a million bucks, $1,000 for a genome analysis to predict who should get that transplant and who should not is an investment, it's not a cost.

Health committee  I'd like to echo David's comments there. The question was how we avoid ending up with a big gap. I would—

Health committee  Right. It's not that we're going to end up with a big gap. The point I was going to make is that we're at the precipice, so we need to work quickly.

Health committee  Thank you very much for the opportunity to address you today. I understand you're interested in hearing about the nature of our research: success stories, challenges, and recommendations. I'll begin by providing a very brief history of the BC Cancer Agency Genome Sciences Centre, which is the entity I direct.